07:41 AM EST, 01/29/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q4 non-GAAP earnings Wednesday of $0.71 per diluted share, down from $1.00 a year earlier.

Analysts polled by FactSet expected $0.71.

Net revenue for the quarter ended Dec. 31 was $4.23 billion, down from $4.46 billion a year earlier.

Analysts surveyed by FactSet expected $4.15 billion.

For 2025, the drug maker said it expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.96 on revenue of $17.09 billion.

Teva shares were down by more than 5% in premarket trading.